TREATMENT OF BEHAVIORAL IMPAIRMENT IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.
1 . A method of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE), the method comprising:
transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein behavioral problems are treated in the subject.
2 . The method of claim 1 , wherein treatment includes a meaningful improvement in quality of life as measured by an improvement in the Epilepsy and Learning Disabilities Quality of Life (ELDQOL) scale within 2 weeks, 4 weeks, or 8 weeks.
3 . The method according to claim 1 , wherein treatment includes a meaningful decrease in sleep disturbance as determined by an improvement of the Sleep Disturbance Scale for Children (SDSC) within 2 weeks, 4 weeks, or 8 weeks.
4 . The method according to claim 1 , wherein treatment includes a meaningful improvement in adaptive behavior as determined by a decrease in the Vineland Adaptive Behavior Scale™-3 (VABS-3) within one month or two months.
5 . The method according to claim 1 , wherein treatment includes a meaningful improvement in caregiver stress as measured by an improvement the University of Washington Caregiver Stress Scale within 2 weeks, 4 weeks, or 8 weeks.
6 . The method according to claim 1 , wherein treatment includes a meaningful improvement in every day satisfaction and well-being.
7 . The method according to claim 1 , wherein treatment includes a meaningful improvement in cognition and awareness.
8 . The method according to claim 1 , wherein the subject has no erythema or minimal erythema.
9 . The method according to claim 1 , wherein the treatment includes a meaningful monthly reduction in focal impaired awareness seizures and convulsive seizures.
10 . The method according to claim 1 , wherein the subject has Lennox-Gastaut or Dravet Syndrome and is a 50% responder within 30 days.
11 . The method according to claim 1 , wherein the effective amount of CBD is 250, 500, 750, or 1000 mg total daily.
12 . The method according to claim 1 , wherein the CBD is administered in a single daily dose.
13 . The method according to claim 1 , wherein the CBD is administered in two daily doses.
14 . The method according to claim 1 , wherein the CBD is a synthetic CBD.
15 . The method according to claim 1 , wherein the CBD is botanically derived.
16 . The method of claim 15 , wherein the CBD is purified.
17 . The method according to claim 1 , wherein subject having developmental and epileptic encephalopathy (DEE) comprises the subject having SYNGAP1 encephalopathy.